{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:19:28Z","timestamp":1763356768425,"version":"3.45.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2024GXNSFBA010039","2024GXNSFBA010253"],"award-info":[{"award-number":["2024GXNSFBA010039","2024GXNSFBA010253"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003454","name":"Guangxi Zhuang Autonomous Region Health Department","doi-asserted-by":"publisher","award":["Z2012276"],"award-info":[{"award-number":["Z2012276"]}],"id":[{"id":"10.13039\/501100003454","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuroendocrine neoplasms (NENs) represent a relatively rare yet heterogeneous group of neoplasms arising from diverse anatomical origins. The inherent variability in clinical manifestations and gradations of biological aggressiveness pose substantial challenges in diagnostic and therapeutic management. This report presents a diagnostically complex case of postpartum non-functional NENs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 39-years-old female with childhood history of acute pancreatitis presented with intermittent abdominal pain and considered pancreatitis during pregnancy. Initial laboratory evaluation revealed elevated carcinoembryonic antigen levels with normal gastrin, serum glucose, and electrolyte profiles. Contrast-enhanced CT and MRI demonstrated multifocal lesions involving the left pulmonary lobe, pancreatic tail, thyroid gland, appendix, bilateral adnexa, and vertebral bodies. Diagnostic endoscopic evaluation identified a raised lesion at the appendiceal orifice, while bronchoscopic visualization revealed neoplastic obstruction in the lingular segment of the left upper lobe. 68Ga-DOTANOC PET\/CT confirmed widespread somatostatin receptor-negative lesions (excluding thyroid nodules), suggesting receptor heterogeneity. Comprehensive genomic profiling failed to identify clinically actionable mutations. Histopathological analysis of biopsy specimens established two distinct primaries: pulmonary atypical carcinoid (Ki-67 proliferation index \u223c30%) and appendiceal neuroendocrine neoplasm (WHO G2, Ki-67 \u223c5%). Following multidisciplinary tumor board consensus, the patient was diagnosed with synchronous primary NETs (pulmonary and appendiceal origin) with multisystem metastases, initiating CAPTEM chemotherapy regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Synchronous non-functional NENs with metastases remain exceptionally rare in clinical practice. The predominant presentation with non-specific abdominal pain significantly amplifies diagnostic complexity in such cases. This underscores the necessity for heightened clinical vigilance for NENs when evaluating atypical presentations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1619565","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:16:52Z","timestamp":1763356612000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-functional, non-mutated multifocal neuroendocrine neoplasms in a postpartum female: a Case Report of an infrequent disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Fangmei","family":"Ling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenkai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms.","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas.","volume":"40","author":"Tang","year":"2016","journal-title":"Am J Surg Pathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/ajcp\/aqaf013","article-title":"Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms.","volume":"163","author":"Sun","year":"2025","journal-title":"Am J Clin Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/CM9.0000000000002643","article-title":"Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States.","volume":"136","author":"Zheng","year":"2023","journal-title":"Chin Med J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States.","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e13264","DOI":"10.1111\/jne.13264","article-title":"Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021.","volume":"35","author":"Thiis-Evensen","year":"2023","journal-title":"J Neuroendocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.semcancer.2021.04.011","article-title":"Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs).","volume":"79","author":"Effraimidis","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: a review of neuroendocrine tumors and carcinomas.","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia."},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Comprehensive Cancer Netw."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1351624","DOI":"10.3389\/fendo.2024.1351624","article-title":"Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.","volume":"15","author":"Andersen","year":"2024","journal-title":"Front Endocrinol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/bjc.2015.397","article-title":"Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.","volume":"113","author":"Vollbrecht","year":"2015","journal-title":"Br J Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1158\/1078-0432.CCR-20-1804","article-title":"Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).","volume":"26","author":"Puccini","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/endrev\/bnad006","article-title":"Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward?","volume":"44","author":"Garcia-Carbonero","year":"2023","journal-title":"Endocr Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.1038\/s41467-025-63091-0","article-title":"Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.","volume":"16","author":"Nassar","year":"2025","journal-title":"Nat Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1053\/j.semdp.2024.08.001","article-title":"Well-differentiated neuroendocrine tumors of the appendix: Diagnosis, differentials, and disease progression.","volume":"41","author":"Navale","year":"2024","journal-title":"Semin Diagn Pathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/JTO.0000000000000419","article-title":"Atypical carcinoid tumor of the lung: A surveillance, epidemiology, and end results database analysis.","volume":"10","author":"Steuer","year":"2015","journal-title":"J Thorac Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.3760\/cma.j.issn.0366-6999.2012.17.010","article-title":"Long-term outcomes of surgical treatment for pulmonary carcinoid tumors: 20 years\u2019 experience with 131 patients.","volume":"125","author":"Zhong","year":"2012","journal-title":"Chin Med J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00268-014-2451-0","article-title":"Role of ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.","volume":"38","author":"Miller","year":"2014","journal-title":"World J Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13073-022-01083-1","article-title":"Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors.","volume":"14","author":"M\u00e4kinen","year":"2022","journal-title":"Genome Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/cancers15061861","article-title":"Tumour heterogeneity and the consequent practical challenges in the management of gastroenteropancreatic neuroendocrine neoplasms.","volume":"15","author":"Reccia","year":"2023","journal-title":"Cancers."},{"key":"B24","first-page":"921","article-title":"Expression pattern of CDX2, estrogen and progesterone receptors in primary gastroenteropancreatic neuroendocrine tumors and metastases.","volume":"36","author":"Zimmermann","year":"2016","journal-title":"Anticancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/MPA.0000000000000203","article-title":"Expression of estrogen-induced genes and estrogen receptor beta in pancreatic neuroendocrine tumors: implications for targeted therapy.","volume":"43","author":"Estrella","year":"2014","journal-title":"Pancreas."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e13465","DOI":"10.1111\/jne.13465","article-title":"Neuroendocrine tumours and pregnancy: real-world data from an European neuroendocrine tumour centre of excellence.","volume":"37","author":"Ratnayake","year":"2025","journal-title":"J Neuroendocrinol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/joim.12747","article-title":"The role of pregnancy, perinatal factors, and hormones in maternal cancer risk: a review of the evidence.","volume":"283","author":"Troisi","year":"2018","journal-title":"J Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/AOG.0000000000002350","article-title":"Committee opinion no. 723 summary: guidelines for diagnostic imaging during pregnancy and lactation.","volume":"130","year":"2017","journal-title":"Obstet Gynecol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/BF03350903","article-title":"Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.","volume":"27","author":"Panzuto","year":"2004","journal-title":"J Endocrinol Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A\u2013biological function and clinical utility in neuro endocrine tumor disease.","volume":"17","author":"Modlin","year":"2010","journal-title":"Ann Surg Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/ERC-17-0269","article-title":"Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.","volume":"25","author":"Marotta","year":"2018","journal-title":"Endocr Relat Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00292-025-01415-z","article-title":"Neuroendokrine neoplasien.","volume":"46","author":"Chouchane","year":"2025","journal-title":"Pathologie."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00259-011-1846-5","article-title":"Molecular imaging with 68Ga-SSTR PET\/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.","volume":"38","author":"Kaemmerer","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B34","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI procedure standard\/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors.","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy.","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1002\/cam4.2259","article-title":"Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: a single-center study.","volume":"8","author":"Song","year":"2019","journal-title":"Cancer Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4067\/s0034-98872021000600888","article-title":"Update on neuroendocrine tumors.","volume":"149","author":"Carrillo","year":"2021","journal-title":"Revista m\u00e9dica de Chile."},{"key":"B38","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.3748\/wjg.v21.i32.9512","article-title":"Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management.","volume":"21","author":"Cloyd","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society (NANETS).","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jtho.2020.06.021","article-title":"Commonwealth neuroendocrine tumour research collaboration and the north american neuroendocrine tumor society guidelines for the diagnosis and management of patients with lung neuroendocrine tumors: an international collaborative endorsement and update of the 2015 European neuroendocrine tumor society expert consensus guidelines.","volume":"15","author":"Singh","year":"2020","journal-title":"J Thoracic Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/annonc\/mdz222","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.","volume":"30","author":"Pavel","year":"2019","journal-title":"Ann Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/cas.13427","article-title":"Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.","volume":"109","author":"Fazio","year":"2018","journal-title":"Cancer Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2217\/fon-2016-0434","article-title":"Capecitabine and temozolomide in grade 1\/2 neuroendocrine tumors: a spanish multicenter experience.","volume":"13","author":"Crespo","year":"2017","journal-title":"Future Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.19401\/j.cnki.1007-3639.2025.01.010","article-title":"China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition).","volume":"35","year":"2025","journal-title":"China Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s12020-019-01838-8","article-title":"The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice.","volume":"64","author":"Alexandraki","year":"2019","journal-title":"Endocrine."},{"key":"B47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000457954","article-title":"Bone metastases in patients with neuroendocrine neoplasm: Frequency and clinical, therapeutic, and prognostic relevance.","volume":"106","author":"Scharf","year":"2018","journal-title":"Neuroendocrinology."},{"key":"B48","first-page":"57","article-title":"Metastatic neuroendocrine pancreatic tumor - case report.","volume":"11","author":"Radu","year":"2018","journal-title":"J Med Life."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1619565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:16:55Z","timestamp":1763356615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1619565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":48,"alternative-id":["10.3389\/fmed.2025.1619565"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1619565","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1619565"}}